Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross
Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 72; DOI: 10.1186/s40425-017-0276-8